TrialBMC cancer2006

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.

Helmut Friess et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.